Dyslipidemia is strongly associated with raised plasma glucose levels and insulin resistance, and genome-wide association studies have identified 95 loci that explain a substantial proportion of the variance in blood lipids. However, the loci's effects on glucose-related traits are largely unknown. We have studied these lipid loci and tested their association collectively and individually with fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), and insulin resistance in two independent cohorts: 10,995 subjects from LifeLines and 2,438 subjects from PREVEND. In contrast to the positive relationship between dyslipidemia and glucose traits, the genetic predisposition to dyslipidemia showed a pleiotropic lowering effect on glucose traits.
dividing the risk scores by the maximum risk. Thus the unweighted risk model can be described as ; where is the number of risk alleles for the j th SNP in the i th individual, coding as 0 for homozygous non-risk alleles, 1 for heterozygous genotype, or 2 for homozygous risk alleles; n is the total number of associated SNPs per lipid trait. The weighted risk score is described as ; where j refers to the estimated effect size for the j th SNP.
Association between the lipid SNPs and the levels of blood lipids. The triglyceride level was log 10 transformed. The residual lipid levels were obtained using linear regression model adjusting for covariates: age, age 2 , and sex. The model is described as y i = age i + age i 2 + sex i + e i (equation
1); where y i refers to an observed lipid level (TG, HDL-C, LDL-C or total cholesterol) for the i th
individual and e i is the remaining residual. The residuals were used as a phenotypic trait and subjected to a Spearman correlation analysis with the lipid risk scores in the Lifelines and PREVEND cohorts, respectively. The association with individual SNPs was tested using a linear regression between the SNP genotype and the lipid residuals. We performed a meta-analysis to combine the effect of the LifeLines and PREVEND data using a weighted Z-score approach. As all the tested SNPs are well-established lipid loci, we felt no need to control the false discovery rate. Nominal associations at P < 0.01 were reported, to have higher confidence in the effect direction of the association.
Association between the lipid risk scores and the levels of glucose-related traits. The HOMA-IR level was log 10 transformed. The residual glucose-related traits were obtained using equation 1, adjusting for the covariates age, age 2 , and sex. The residuals were used as a phenotypic trait and subjected to a Spearman correlation analysis with the lipid risk scores. individual and e i ' refers to the residuals for glucose traits that are independent of lipid levels. The residuals represent the proportion of variation in glucose traits that cannot be explained by blood lipid levels. Thus, the residuals were used as lipid-independent glucose traits and subjected to Spearman correlation analysis with lipid risk scores. The association identified between lipid loci and the residuals is independent from blood lipid levels, referred to as pleiotropic association.
Lipid levels and glucose-related traits often show strong correlation at biological and metabolic levels. In this way, the model can remove not only the genetic variation in glucose-related traits that propagates through blood lipids in path A, but also additional variation explained by blood lipids through other (biological or metabolic) sources. As a result, the model will have more power to detect pleiotropic genetic associations.
The pleiotropic association between individual lipid SNPs and glucose-related traits. To test
the pleiotropic association between individual lipid SNPs and glucose-related traits, we performed linear regression analysis between the SNP genotype and glucose-related traits after adjusting the blood lipids using equation 2. We performed a meta-analysis to combine the effect of the LifeLines and PREVEND data using a weighted Z-score approach. Nominal associations at P < 0.01 were reported.
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RESULTS
Observed association between lipid SNPs and lipid levels in both cohorts. We observed a significant positive correlation between lipid risk scores and the lipid levels in our cohorts. The weighted risk scores outperformed the unweighted risk scores (Supplemental Table 5 ) and explained a substantial proportion of the variation in lipid levels: 4.95% for HDL-C, 3.61% for LDL-C, 3.61% for TG and 4.41% for TC in LifeLines ( Figure 2 ); 3.69% for HDL-C, 1.90%
LDL-C; 4.37% TG and 2.07% for TC in PREVEND. As the weighted risk score was superior to the unweighted risk score, we used the former in all further analysis. The single SNP association 
Significant correlation at phenotypic level but no association observed between lipid risk
scores and glucose-related traits. We assessed three different glucose-related traits in two independent cohorts: fasting plasma glucose from both the LifeLines and PREVEND cohorts, HbA1c from LifeLines, and HOMA-IR from PREVEND. After adjusting for covariates (age, age 2 and sex), we observed a significant correlation between glucose-related traits and the lipid levels. Consistent with epidemiological observations, individuals who have higher TG, TC and LDL-C levels, or lower HDL-C levels, tend to have higher levels of glucose-related traits ( Table   2 ). Most of the strongest correlations were observed between TG and glucose-related traits.
Despite strong correlations at the phenotypic level, we only observed a weak correlation between the TG risk score and HbA1c level in the LifeLines cohort (Supplemental Table 6 ). However, Pleiotropic association between lipid risk scores and glucose-related traits. We further regressed out the phenotypic correlation structure between lipids and glucose-related traits and obtained lipid-independent glucose traits. At the genetic level, we observed an opposite effect between dyslipidemia and glucose-related traits in the two independent cohorts: higher TG, TC
and LDL-C risk scores, or lower HDL-C risk scores, were correlated with lower glucose-related traits (Table 3) HbA1c, and 9 SNPs for HOMA-IR ( Figure 3 and Supplemental Table 7 ). For 8 out of 15 loci, the genetic predisposition for dyslipidemia (higher levels of TG, TC, LDL-C and lower HDL-C level) and TIMD4 (Figure 3 ). For instance, the rs7205804-G allele at the CETP locus has been reported to be associated with higher levels of TG (5). In our cohorts this allele was consistently associated with higher levels of TG (P=0.014), LDL cholesterol (P=3.1x10 -6 ) and with lower HDL cholesterol (P=6.2x10 -70 ). It was also significantly associated with lower levels of FPG (P=9.2x10 -4 ), HbA1c (P=9.2x10 -3 ) and HOMA-IR (P=3.2x10 -3 ). Hence, an individual with the G allele will have a higher probability of developing dyslipidemia, while at the same time being genetically predisposed to lower levels of FPG, HbA1c and HOMA-IR. The same phenomenon was observed for another SNP, rs3764261, at the same locus, which is strongly linked with rs7205804 ( Figure 3 ). We further compared the allelic directions of SNPs on glucose-related traits before and after adjusting for lipids. The allelic directions were consistent, but the associations became stronger after adjusting for lipid levels (Supplemental Table 8 ). This suggests that regressing out the genetic and other variation that could be explained by blood lipids did indeed increase the power for detecting pleiotropic effects.
DISCUSSION
In this study, we investigated the impact of lipid-associated SNPs on three glucose-related traits in more than 13,000 subjects from two independent cohorts. We investigated two possible effectpaths ( Figure 1 ) to answer the questions: (1) whether lipid-associated SNPs affect glucoserelated traits by mediating blood lipids (path A), or (2) whether lipid-associated SNPs have pleiotropic effects on glucose-related traits independent of blood lipids level (path B). We first observed no significant correlation between the genetic risk scores for dyslipidemia and glucose- Out of 95 established lipid loci that we investigated, 13 and 16 loci were reported to associate with fasting glucose or diabetes, respectively, at a nominal P < 0.05 level, by the most recent paper from the Global Lipids Genetics Consortium (6). However, it is still not clear whether these associations are pleiotropic or mediated by blood lipid levels. In our study, we observed that 6 of the previously reported loci were pleiotropically associated with glucoserelated traits at P < 0.01 (Figure 4 ). In total, we detected such pleiotropic associations for 15 loci. allele at GATAD2A/CILP2/PBX4 has been associated with an increased risk of T2D (33), the TGlowering allele at the PNPLA3 locus has also been associated with a higher risk of T2D in obese individuals (34), and the WHR (Waist-Hip ratio)-decreasing allele at the GRB14 locus has been associated with higher fasting plasma glucose levels (35). This evidence is in line with our observation that genetic predisposition to dyslipidemia is associated with lower level of fasting plasma glucose, HbA1c and HOMA-IR. However, it remains poorly understood how these genes affect both glucose and lipids or the mechanisms involved. Glucose utilization and lipid synthesis are highly intertwined in many tissues including liver, adipose tissues and muscle, and different mechanisms can be involved. Thus, a systems biology approach is crucial to mechanically illustrate the complex interplay between lipogenesis and glycolysis.
Our analysis has presented a model for the detection of genetic pleiotropy. With expanding work on ever-larger GWA studies on a wide variety of phenotypes, it is increasingly being observed that some risk loci show associations with multiple phenotypes. Understanding pleiotropic effects on complex traits has important clinical implications, e.g., understanding the comorbidity of multiple diseases and reducing unexpected side-effects of therapeutic interventions. As recently discussed, systematic detection of such effects remains challenging and requires new methodological frameworks (36). Phenotypes that share more genetic background typically show higher correlations at the phenotypic level. Our study clearly showed that regressing out the genetic and other variation explained by blood lipids substantially increased the power to detect genetic pleiotropy.
In conclusion, for the first time, we have systematically assessed the pleiotropic effect of lipid-associated SNPs on glucose-related traits. Although, at a clinical level, dyslipidemia is associated with elevated plasma glucose levels and insulin resistance, we observed that the The effect-path A indicates that lipid-associated SNPs affect blood lipid levels that could predispose to variation in glucose-related traits. In this path, lipid-associated SNPs are associated with glucose-related traits, but this association depends on blood lipid levels (no pleiotropic effect). After regressing out the effects of blood lipids, the association should disappear. The effect-path B indicates the pleiotropic effect of lipid-associated SNPs on glucose-related traits, which is independent of blood lipid levels. After regressing out the effects of blood lipids, the association between lipid SNPs and glucose-related traits should remain significant. 
